BIIB Chart

1 Month

	Date	Diff	Articles
	2025-05-05	-1.4 %	Biogen's stock (NASDAQ: BIIB) declined by 1.4% following a target price reduction by Canaccord Genuity Group, which lowered its forecast from $265 to $220, despite the company maintaining a buy rating. The drop in stock price is attributed to analysts lowering their price targets and ratings for Biogen, alongside the company's recent earnings miss, where its earnings per share fell short of expectations.
Biogen's stock (NASDAQ: BIIB) declined by 1.4% following a target price reduction by Canaccord Genuity Group, which lowered its forecast from $265 to $220, despite the company maintaining a buy rating. The drop in stock price is attributed to analysts lowering their price targets and ratings for Biogen, alongside the company's recent earnings miss, where its earnings per share fell short of expectations. Biogen (NASDAQ:BIIB) stock dropped by 1.4% following a downgraded price target by HC Wainwright, which lowered it to $187.00, indicating bearish sentiment among analysts. Biogen Inc. (NASDAQ: BIIB) experienced a 1.4% decline in stock value following its quarterly earnings report that missed consensus estimates, causing investor concern despite some analysts raising future earnings predictions. The decline in Biogen's stock was primarily due to the company reporting earnings of $3.02 per share, which fell short of the expected $3.26, raising concerns among investors about its current performance. Biogen Inc. (NASDAQ:BIIB) stock fell by 1.4% due to multiple price target reductions from various research firms and a recent quarterly earnings report that showed missed earnings expectations despite revenue growth. Biogen (BIIB) stock declined by 1.4% after HC Wainwright lowered its target price from $241.00 to $187.00, amidst a series of downgrades from several analysts highlighting concerns over the company’s earnings performance.
	2025-05-02	+2.15 %	Biogen (BIIB) stock rose by 2.15% due to the positive outlook and a new price target of $199.00 set by Truist Financial, indicating analyst confidence in the company's future performance.
Biogen (BIIB) stock rose by 2.15% due to the positive outlook and a new price target of $199.00 set by Truist Financial, indicating analyst confidence in the company's future performance. Biogen's (NASDAQ: BIIB) stock rose 2.15% following the release of its quarterly earnings report, which, despite missing earnings estimates, revealed higher-than-expected revenue growth, leading to increased investor interest and a positive market response. Biogen (BIIB) stock rose 2.15% following a positive price target adjustment by Truist Financial, which increased its price target to $199.00, indicating investor confidence in the company's prospects. Biogen (NASDAQ:BIIB) stock rose 2.15% despite a decrease in target prices from several analysts, possibly due to stronger-than-expected quarterly revenue of $2.43 billion, which exceeded analysts' estimates.
	2025-05-01	-0.12 %	Biogen stock has experienced a slight decline of 0.12% despite beating first-quarter expectations and reporting strong sales for its new drugs, Leqembi and Skyclarys, likely due to market volatility or profit-taking after the positive earnings report.
Biogen stock has experienced a slight decline of 0.12% despite beating first-quarter expectations and reporting strong sales for its new drugs, Leqembi and Skyclarys, likely due to market volatility or profit-taking after the positive earnings report.
	2025-04-30	+0.76 %	Biogen (NASDAQ:BIIB) stock rose by 0.76% despite being downgraded from "strong-buy" to "hold" by HSBC Global Research, as well as facing price target reductions from several analysts, possibly due to its solid earnings performance and ongoing interest from institutional investors.
Biogen (NASDAQ:BIIB) stock rose by 0.76% despite being downgraded from "strong-buy" to "hold" by HSBC Global Research, as well as facing price target reductions from several analysts, possibly due to its solid earnings performance and ongoing interest from institutional investors.
	2025-04-29	+0.88 %	Biogen (NASDAQ:BIIB) stock rose 0.88% in response to positive market sentiment ahead of its anticipated Q1 2025 earnings report, where analysts expect it to exceed earnings expectations.
Biogen (NASDAQ:BIIB) stock rose 0.88% in response to positive market sentiment ahead of its anticipated Q1 2025 earnings report, where analysts expect it to exceed earnings expectations. Biogen Inc. (BIIB) shares rose by 0.88% despite a downgrade in Q2 earnings estimates by investment analysts, reflecting investor confidence in the company following its recent quarterly earnings beat and ongoing interest from institutional investors.
	2025-04-25	-0.56 %	Biogen (NASDAQ:BIIB) stock declined by 0.56% after The Goldman Sachs Group lowered its price target for the company from $219.00 to $197.00, which contributed to negative market sentiment despite maintaining a "buy" rating.
Biogen (NASDAQ:BIIB) stock declined by 0.56% after The Goldman Sachs Group lowered its price target for the company from $219.00 to $197.00, which contributed to negative market sentiment despite maintaining a "buy" rating.
	2025-04-23	-0.61 %	Biogen (NASDAQ:BIIB) stock decreased by 0.61% following various downgrades and price target reductions by multiple investment analysts, although Royal Bank of Canada raised its price objective for the stock.
Biogen (NASDAQ:BIIB) stock decreased by 0.61% following various downgrades and price target reductions by multiple investment analysts, although Royal Bank of Canada raised its price objective for the stock. Biogen (BIIB) stock declined by 0.61% as investors remain cautious about the future profitability of biotech firms, particularly in light of expected patent expirations affecting major players in the industry, including Biogen.